The FDA has granted fast-track approval for a groundbreaking gene therapy indicated for a rare genetic disorder called aromatic L-amino acid decarboxylase (AADC) deficiency.
In a recent study, [8] the antinociceptive effects of two oral formulations of ibuprofen, ibuprofen acid tablets and an effervescent formulation, were compared. The effervescent formulation proved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback